*Corresponding author:Atsushi Imai, Institute of Endocrine-related Cancer, Matsunami General Hospital, Kasamatsu, Gifu, Japan, Tel: 815823880111; Email: email@example.com
Received: December 21, 2017; Published: January 05, 2018
To view the Full Article Peer-reviewed Article PDF
Clinical trials are a key resource for the discovery of new diagnostic, treatment and prevention methods for disease. Many of today’s most introduced prevention and treatment modalities are based on previous clinical trial results. Clinical trials are an important part of improving quality of health care . Facilitators of participation in clinical trials have been linked to recommendations by reliable health care providers, a supportive family, satisfactory doctor-patient relationship that depends on culture, financial incentives, anticipation of a personal benefit to participants, convenience to participants and culturally appropriate advertisements . To address such facilitators and barriers of clinical trial participation in communities, we report our institutional review board (IRB) of Matsunami General Hospital . A typical central medical institution anchor of the region, Japan.
Keywords: IRB; Contracted Clinical Trial; Medical Institution Anchor of the Region; Medical Research